DekaBank Deutsche Girozentrale’s Janux Therapeutics JANX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$656K	Hold	49,500	–	–	﹤0.01%	849
2025 Q4	$2.04M	Hold	49,500	–	–	﹤0.01%	766
2025 Q3	$2.02M	Hold	49,500	–	–	﹤0.01%	744
2025 Q2	$2.04M	Hold	49,500	–	–	﹤0.01%	739
2025 Q1	$1.88M	Hold	49,500	–	–	﹤0.01%	745
2024 Q4	$1.78M	Hold	49,500	–	–	﹤0.01%	772
2024 Q3	$1.88M	Hold	49,500	–	–	﹤0.01%	771
2024 Q2	$1.88M	Hold	49,500	–	–	﹤0.01%	774
2024 Q1	$1.88M	Hold	49,500	–	–	﹤0.01%	771
2023 Q4	$579K	Hold	49,500	–	–	﹤0.01%	1008
2023 Q3	$484K	Hold	49,500	–	–	﹤0.01%	1021
2023 Q2	$571K	Hold	49,500	–	–	﹤0.01%	1002
2023 Q1	$574K	Hold	49,500	–	–	﹤0.01%	989
2022 Q4	$668K	Hold	49,500	–	–	﹤0.01%	972
2022 Q3	$669K	Hold	49,500	–	–	﹤0.01%	985
2022 Q2	$566K	Buy	+49,500	New	+$586K	﹤0.01%	1000
2022 Q1	–	Sell	-45,000	Closed	-$892K	–	1391
2021 Q4	$892K	Buy	+45,000	New	+$943K	﹤0.01%	959

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DekaBank Deutsche Girozentrale's JANX Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale held its Janux Therapeutics (JANX) position steady in Q1 2026 at 49,500 shares worth $656K. The position accounts for ﹤0.01% of the portfolio, ranked #849.

DekaBank Deutsche Girozentrale first reported a position in JANX in Q4 2021 and has held it in 17 quarters since. The position peaked at $2.04M in Q4 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

DekaBank Deutsche Girozentrale held 49,500 shares of Janux Therapeutics worth $656K as of Q1 2026.
DekaBank Deutsche Girozentrale left its Janux Therapeutics share count unchanged in Q1 2026.
Janux Therapeutics made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q1 2026, its #849 holding.
DekaBank Deutsche Girozentrale first reported a position in Janux Therapeutics in Q4 2021 and has held it in 17 quarters since.
DekaBank Deutsche Girozentrale's Janux Therapeutics position peaked at $2.04M in Q4 2025.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.